Phenomenon or Process
Pressure Points: Understanding Their Role in Self-Defense and Health
Pressure Points, Self-Defense, Knockout Techniques, Acupressure, Health Benefits, Pain Relief
Kyverna’s CAR-T Relapse in Lupus Dents Autoimmune Hopes Amid Biotech Gold Rush
Kyverna, CAR-T, Lupus, Autoimmune Disease, Biotech, Gold Rush, Relapse, Clinical Trials, Gene Therapy
Bicycle Therapeutics Gears Up for Future Milestones with $555 Million Capital Infusion
Bicycle Therapeutics, funding, catalysts, biotechnology, drug development, clinical trials, investors, capital infusion, milestones.
Merck KGaA Evades Legal Action Following DOJ Collaboration on China Export Investigation
Merck KGaA, DOJ, China, export scheme, cooperation, investigation, prosecution avoidance
WHO Negotiations Extended for Global Pandemic Agreement
World Health Organization (WHO), pandemic accord, international agreement, global health, deadline, negotiations, public health emergency, disease outbreaks.
Pharmaceutical Industry’s Public Image Deteriorates Post-Pandemic Era
Pharmaceutical industry, reputation, pandemic, public opinion, COVID-19, vaccine development, drug pricing, transparency.
Roche’s Ocrevus Demonstrates Near-Complete Reduction of Relapse and Lesions in Multiple Sclerosis
Ocrevus, Roche, Multiple Sclerosis (MS), Relapse reduction, Lesion reduction, Clinical and MRI measures
AstraZeneca’s Ultomiris Gains FDA Approval for Rare Autoimmune Condition – NMOSD
AstraZeneca, Ultomiris, ravulizumab-cwvz, FDA Approval, Rare Autoimmune Disease, Neuromyelitis Optica Spectrum Disorder (NMOSD), Long-acting C5 complement inhibitor, Phase 3 CHAMPION-NMOSD Trial, Reduced Relapse Rate, Dosing Frequency
Inventiva Halts Enrollment in Phase 3 MASH Study Following Patient Raised Liver Enzyme Incident
Clinical Research, lanifibranor, Incident
Lonza closes plant in China but CDMO’s sales signal an uptick in industry
Plants, China, Signal, Industry, Congestive heart failure